Now showing items 1-3 of 3
Research and Development of Drugs for Developing Countries Faces Many Barriers
R&D for neglected diseases faces a number of barriers. In order to expand R&D, all of the actors – governments, companies, and NGOs, among others – need to work together on solutions. The limitations of the prize fund model ...
Clinical Trials Are Heavily Influenced by Drug Companies
Despite its stated interest in openness and transparency, Health Canada continues to deny the public access to information about clinical trials. It is also moving at a snail’s pace in developing a policy on clinical trials ...
Drug Safety Is Influenced More by Business Interests Rather Than Public Health
The safety of pharmaceutical drugs in Canada is a concern. While Health Canada is given the power to measure safety and approve drugs, the process has its limits. There is a growing trend towards practicing “risk management” ...